Company profile: Traws Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage small molecule oral therapies, including investigational inhibitors for COVID-19 (TRX01/ratutrelvir) and pandemic influenza (TRX100/tivoxavir marboxil), and narazaciclib, a proprietary multi-kinase CDK4-plus inhibitor in trials for refractory endometrial and metastatic breast cancer.
Products and services
- Narazaciclib: A proprietary multi-kinase CDK4-plus inhibitor in clinical trials for refractory endometrial and metastatic breast cancer, targeting pathways involved in drug resistance
- TRX01 (ratutrelvir): An investigational oral inhibitor of the SARS‑CoV‑2 main protease for COVID‑19, engineered to reduce drug interactions and broaden patient eligibility for treatment
- TRX100 (tivoxavir marboxil): A cap‑independent endonuclease inhibitor under development to treat and prevent pandemic influenza, effective against drug‑resistant and pandemic‑potential strains
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Traws Pharma
Varian
HQ: United States
Website
- Description: Provider of medical devices and software for treating cancer and other conditions via radiotherapy, radiosurgery, proton therapy, and brachytherapy. Offers informatics software; products such as Ethos Adaptive Radiotherapy System, IntelliBlate Microwave Ablation System, Laguna Thrombectomy System, and Varian Marketplace, plus Advanced Oncology Solutions providing clinical and professional support and workflow solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Varian company profile →
Immunome
HQ: United States
Website
- Description: Provider of immunotherapy and antigen discovery solutions, developing targeted therapies including IM-4320 (IL-38-focused tumor control) and 177Lu-FAP radioligand for solid tumors aimed at enhanced tumor radiation delivery. Offers Memory B cell hybridoma technology, a Targeted Effector platform using small-molecule ligands for payload delivery and radioligand design, and the Immunome Discovery Engine to identify novel therapeutic targets and antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunome company profile →
VisionGate
HQ: United States
Website
- Description: Provider of an automated 3D cell imaging platform for early cancer detection and prevention.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VisionGate company profile →
TCR2 Therapeutics
HQ: United States
Website
- Description: Provider of a unique proprietary TRuC™ platform developed by a discovery-stage pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TCR2 Therapeutics company profile →
Onxeo
HQ: France
Website
- Description: Provider of oncology drug R&D and platforms, offering Beleodaq (belinostat), a histone deacetylase inhibitor marketed in the US for injection; Livatag, a nanoparticle doxorubicin in Phase III for primary liver cancer; and pipeline programs including platON, a decoy oligonucleotide platform for cancer and inflammatory diseases; AsiDNA, a DNA-repair decoy; and VIO-01, a pan‑DDR decoy activating STING.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onxeo company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Traws Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Traws Pharma
2.2 - Growth funds investing in similar companies to Traws Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Traws Pharma
4.2 - Public trading comparable groups for Traws Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →